Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 22848626)

1.

Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation.

McClure J, Lovelace ES, Elahi S, Maurice NJ, Wagoner J, Dragavon J, Mittler JE, Kraft Z, Stamatatos L, Horton H, De Rosa SC, Coombs RW, Polyak SJ.

PLoS One. 2012;7(7):e41832. doi: 10.1371/journal.pone.0041832. Epub 2012 Jul 25. Erratum in: PLoS One. 2012;7(10). doi: 10.1371/annotation/78ba072a-6b7a-430a-8fcd-ef020e4fc458. Stamatatos, Leonidis [corrected to Stamatatos, Leonidas].

2.

Analysis of protein kinase C theta inhibitors for the control of HIV-1 replication in human CD4+ T cells reveals an effect on retrotranscription in addition to viral transcription.

Bermejo M, López-Huertas MR, Hedgpeth J, Mateos E, Rodríguez-Mora S, Maleno MJ, Plana M, Swindle J, Alcamí J, Coiras M.

Biochem Pharmacol. 2015 Apr 15;94(4):241-56. doi: 10.1016/j.bcp.2015.02.009. Epub 2015 Feb 27.

PMID:
25732195
3.

P2X-selective purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and cell-free infection.

Swartz TH, Esposito AM, Durham ND, Hartmann BM, Chen BK.

J Virol. 2014 Oct;88(19):11504-15. doi: 10.1128/JVI.01158-14. Epub 2014 Jul 16.

4.

CD127 expression, exhaustion status and antigen specific proliferation predict sustained virologic response to IFN in HCV/HIV co-infected individuals.

Kared H, Saeed S, Klein MB, Shoukry NH.

PLoS One. 2014 Jul 9;9(7):e101441. doi: 10.1371/journal.pone.0101441. eCollection 2014.

5.

Inhibition of HIV by Legalon-SIL is independent of its effect on cellular metabolism.

McClure J, Margineantu DH, Sweet IR, Polyak SJ.

Virology. 2014 Jan 20;449:96-103. doi: 10.1016/j.virol.2013.11.003. Epub 2013 Nov 27.

6.

HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy.

Murray JM, Zaunders JJ, McBride KL, Xu Y, Bailey M, Suzuki K, Cooper DA, Emery S, Kelleher AD, Koelsch KK; PINT Study Team.

J Virol. 2014 Mar;88(6):3516-26. doi: 10.1128/JVI.03331-13. Epub 2014 Jan 8.

7.

Silybin-mediated inhibition of Notch signaling exerts antitumor activity in human hepatocellular carcinoma cells.

Zhang S, Yang Y, Liang Z, Duan W, Yang J, Yan J, Wang N, Feng W, Ding M, Nie Y, Jin Z.

PLoS One. 2013 Dec 27;8(12):e83699. doi: 10.1371/journal.pone.0083699. eCollection 2013.

8.

The tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4+ T cells from HIV-1 infected patients.

Pogliaghi M, Papagno L, Lambert S, Calin R, Calvez V, Katlama C, Autran B.

AIDS. 2014 Jan 14;28(2):278-81. doi: 10.1097/QAD.0000000000000073.

PMID:
24361684
9.

HIV-1 Vpr accelerates viral replication during acute infection by exploitation of proliferating CD4+ T cells in vivo.

Sato K, Misawa N, Iwami S, Satou Y, Matsuoka M, Ishizaka Y, Ito M, Aihara K, An DS, Koyanagi Y.

PLoS Pathog. 2013;9(12):e1003812. doi: 10.1371/journal.ppat.1003812. Epub 2013 Dec 5.

10.

Inhibition of R5-tropic HIV type-1 replication in CD4⁺ natural killer T cells by γδ T lymphocytes.

Omi K, Shimizu M, Watanabe E, Matsumura J, Takaku C, Shinya E, Takahashi H.

Immunology. 2014 Apr;141(4):596-608. doi: 10.1111/imm.12221.

11.

Characterization of CD4⁺ T-cell immune activation and interleukin 10 levels among HIV, hepatitis C virus, and HIV/HCV-coinfected patients.

Hodowanec AC, Brady KE, Gao W, Kincaid SL, Plants J, Bahk M, Landay AL, Huhn GD.

J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):232-40. doi: 10.1097/QAI.0b013e31829c6de0.

PMID:
24131865
12.

Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.

Cufí S, Bonavia R, Vazquez-Martin A, Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Martin-Castillo B, Barrajón-Catalán E, Visa J, Segura-Carretero A, Bosch-Barrera J, Joven J, Micol V, Menendez JA.

Food Chem Toxicol. 2013 Oct;60:360-8. doi: 10.1016/j.fct.2013.07.063. Epub 2013 Aug 1.

PMID:
23916468
13.

Role of the carbohydrate-binding sites of griffithsin in the prevention of DC-SIGN-mediated capture and transmission of HIV-1.

Hoorelbeke B, Xue J, LiWang PJ, Balzarini J.

PLoS One. 2013 May 31;8(5):e64132. doi: 10.1371/journal.pone.0064132. Print 2013.

14.

Immunosuppressive effect of silymarin on mitogen-activated protein kinase signalling pathway: the impact on T cell proliferation and cytokine production.

Gharagozloo M, Jafari S, Esmaeil N, Javid EN, Bagherpour B, Rezaei A.

Basic Clin Pharmacol Toxicol. 2013 Sep;113(3):209-14. doi: 10.1111/bcpt.12088. Epub 2013 Jun 20.

PMID:
23701595
15.

Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.

Esser-Nobis K, Romero-Brey I, Ganten TM, Gouttenoire J, Harak C, Klein R, Schemmer P, Binder M, Schnitzler P, Moradpour D, Bartenschlager R, Polyak SJ, Stremmel W, Penin F, Eisenbach C, Lohmann V.

Hepatology. 2013 Mar;57(3):953-63. doi: 10.1002/hep.26260. Epub 2013 Feb 7.

16.

GB virus C infection is associated with altered lymphocyte subset distribution and reduced T cell activation and proliferation in HIV-infected individuals.

Stapleton JT, Chaloner K, Martenson JA, Zhang J, Klinzman D, Xiang J, Sauter W, Desai SN, Landay A.

PLoS One. 2012;7(11):e50563. doi: 10.1371/journal.pone.0050563. Epub 2012 Nov 29.

17.

Impact of sustained RNAi-mediated suppression of cellular cofactor Tat-SF1 on HIV-1 replication in CD4+ T cells.

Green VA, Arbuthnot P, Weinberg MS.

Virol J. 2012 Nov 15;9:272. doi: 10.1186/1743-422X-9-272.

18.

In vitro effects of the CCR5 inhibitor maraviroc on human T cell function.

Arberas H, Guardo AC, Bargalló ME, Maleno MJ, Calvo M, Blanco JL, García F, Gatell JM, Plana M.

J Antimicrob Chemother. 2013 Mar;68(3):577-86. doi: 10.1093/jac/dks432. Epub 2012 Nov 14.

19.

Silymarin inhibits cell cycle progression and mTOR activity in activated human T cells: therapeutic implications for autoimmune diseases.

Gharagozloo M, Javid EN, Rezaei A, Mousavizadeh K.

Basic Clin Pharmacol Toxicol. 2013 Apr;112(4):251-6. doi: 10.1111/bcpt.12032. Epub 2012 Dec 24.

PMID:
23121838
20.

VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.

Lori F, De Forni D, Katabira E, Baev D, Maserati R, Calarota SA, Cahn P, Testori M, Rakhmanova A, Stevens MR.

PLoS One. 2012;7(10):e47485. doi: 10.1371/journal.pone.0047485. Epub 2012 Oct 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk